The RIQAS CYFRA 21-1 EQA programme is designed to cover the analysis of CYFRA 21-1 in clinical laboratories when monitoring the response to treatment of cancers such as non-small cell lung carcinoma, cervical, breast and bladder cancer.
Lyophilised material for enhanced stability

Submit results and view reports online via RIQAS.Net
World's largest EQA scheme ensures peer groups are maximised
Monthly reporting for earlier identification of test system errors
Cycle Starts - March 2026
Accredited to ISO17043:2023 standard via RIQAS flexible scope
To find out more about RIQAS EQA or to get in touch with your local Randox Representative, enquire now.
| Description | Frequency | Size | Cat No | |
|---|---|---|---|---|
| CYFRA 21-1 | Monthly | 12 x 1 ml | RQ9175 |
Immunoassay
Immunoassay Speciality 1
Immunoassay Speciality 2